Sedation, sucralfate, and antibiotic use are potential means for protection against early-onset ventilator-associated pneumonia

Clin Infect Dis. 2004 May 15;38(10):1401-8. doi: 10.1086/386321. Epub 2004 Apr 29.

Abstract

To examine risk factors for early-onset ventilator-associated pneumonia (EOP) in patients requiring mechanical ventilation (MV), we performed a prospective cohort study that included 747 patients. Pneumonia was defined as a positive result for a protected quantitative distal sample. EOP was defined as pneumonia that occurred from day 3 to day 7 of MV. Eighty patients (10.7%) experienced EOP. Independent predictors of EOP were male sex (odds ratio [OR], 2.06; 95% confidence interval [CI], 1.18-3.63), actual Glasgow Coma Scale value of 6-13 (OR, 1.95; 95% CI, 1.2-3.18), high Logistic Organ Dysfunction score at day 2 (OR, 1.12 per point; 95% CI, 1.02-1.23), unplanned extubation (OR, 3.19; 95% CI, 1.28-7.92), and sucralfate use (OR, 1.81; 95% CI, 1.01-3.26). Protection occurred with use of aminoglycosides (OR, 0.36; 95% CI, 0.17-0.76), beta -lactams and/or beta -lactamase inhibitors (OR, 0.47; 95% CI, 0.28-0.83), or third-generation cephalosporins (OR, 0.33; 95% CI, 0.16-0.74). Sucralfate use and unplanned extubation are independent risk factors for EOP. Use of aminoglycosides, beta-lactams/ beta-lactamase inhibitors, or third-generation cephalosporins protects against EOP.

Publication types

  • Multicenter Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Aged
  • Anti-Bacterial Agents / therapeutic use*
  • Cohort Studies
  • Female
  • Humans
  • Male
  • Middle Aged
  • Pneumonia, Bacterial / epidemiology
  • Pneumonia, Bacterial / etiology
  • Pneumonia, Bacterial / microbiology
  • Pneumonia, Bacterial / prevention & control*
  • Prospective Studies
  • Respiration, Artificial
  • Risk Factors*
  • Sucralfate / therapeutic use*
  • Time Factors
  • Ventilators, Mechanical / adverse effects*

Substances

  • Anti-Bacterial Agents
  • Sucralfate